Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-XYIMSR-01
- Development stage
- Phase 1
- Lead developer
- Johns Hopkins University
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-XYIMSR-01 is an investigational radiopharmaceutical designed for the diagnostic imaging of clear cell renal cell carcinoma (ccRCC). It is a small-molecule radiotracer that high-affinitively targets Carbonic Anhydrase IX (CAIX), a transmembrane glycoprotein that is constitutively overexpressed in more than 90% of ccRCC cases due to mutations in the von Hippel-Lindau (VHL) gene. The agent consists of a urea-based CAIX ligand conjugated to a DOTA chelator, which is complexed with the gamma-emitting radioisotope Indium-111. This configuration allows for highly specific localization of primary and metastatic ccRCC lesions using Single Photon Emission Computed Tomography (SPECT/CT), facilitating non-invasive diagnosis, staging, and potential monitoring of treatment response.
- Other names
- Indium-111 XYIMSR-01Indium111 XYIMSR-01Indium 111 XYIMSR-01111In-DOTA-XYIMSR-01[111In]XYIMSR-01
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 111In-XYIMSR-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-XYIMSR-01.